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Circulating tumor cells (CTCs) are tumor cells that have detached from primary tumor site and are transported via the circulation
system. The importance of CTCs as prognostic biomarker is leveraged when multiple studies found that patient with cutoff of 5
CTCs per 7.5mL blood has poor survival rate. Despite its clinical relevance, the isolation and characterization of CTCs can be
quite challenging due to their large morphological variability and the rare presence of CTCs within the blood. Numerous methods
have been employed and discussed in the literature for CTCs separation. In this paper, we will focus on label free CTCs isolation
methods, in which the biophysical and biomechanical properties of cells (e.g., size, deformability, and electricity) are exploited for
CTCs detection. To assess the present state of various isolation methods, key performance metrics such as capture efficiency, cell
viability, and throughput will be reported. Finally, we discuss the challenges and future perspectives of CTC isolation technologies.
1. Introduction
Cancer is one of the leading causes of death worldwide.
According to the International Agency for Research on Can-
cer (IARC), there are an estimated 8.2 cancer-related deaths
in 2012, where 90% of them are caused by metastasis [1]. As
a result, metastasis has become the prime prognosis factor in
carcinoma patients. Generally, cancer metastasis involves the
spread of cancer cells, whereby the tumor cells detach from
primary tumor site and be transported via the circulation
system to a distant organ to form secondary tumors. These
cells, which shed into vasculature, are referred to as circulat-
ing tumor cells (CTCs). The presence of CTCs was first dis-
covered by Thomas Ashworth in 1869, after comparing their
morphology to tumor cells from different lesions. Despite his
discovery, its impact on cancer detectionmethodwas lesswell
established in the early stage due to the lack of detailed insight
into the mechanisms of tumor.
In clinical practice, the cancer diagnostics are commonly
performed through radiological imaging modalities such as
traditional radiography (X-ray), magnetic resonance imag-
ing (MRI), computed tomography (CT), positron emission
tomography (PET), or ultrasound. These techniques allow
visualization of internal body structure. Thus, it enables phy-
sicians to delineate the group of tumor cell colonization.
However, there are some pitfalls in these techniques. For
instance, the deficiencies of resolution in imaging modalities
have precluded them to image small numbers of cancer cells
before angiogenic switch, which in turn limit the detection
sensitivity [2, 3]. Furthermore, most of the cases are normally
diagnosed at advanced stages where patients often relapsed
within 24 months of therapeutic intervention [4, 5].
In recent years, the emerging data have challenged the
traditional theory of metastasis sequential development. In
fact, study carried out by Hu¨semann et al. highlights that
CTCs can be found in patients even before a primary tumor
is detected with conventional clinical screening methods [4].
The importance of CTCs is further augmented when there
are increasing evidences about the presence of significance
correlation between the number of circulating tumor cells
and patients survival times. It has been scientifically validated
by prospective multicenter studies that patient with cutoff of
5 ormore CTCs per 7.5mL of blood would have poor survival
rate [4, 6, 7]. A similar analysis of prognostic value of CTCs
among colorectal cancer patient was performed by Allen and
El-Deiry. Their study points out that the median progression
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free survival (PFS) and overall survival rates were twice as
high for patient with less than 3 CTCs per 7.5mL of blood;
thus, it has confirmed the previous findings. Additionally,
this group also presented significant data which showed that
patients with elevated CTCs density after therapy would
have poor survival rate [8]. Nevertheless, simple enumeration
of CTCs is inadequate because cancer is a constellation of
diseases with various pathologic alterations that might cause
prognosis. Since the ability in analyzing proliferation of viable
CTCs has still been lacking, it is difficult to assess CTC infor-
mation which is the representative of cellular information
available in primary tumor. In fact, the dimension of CTC
biological feature is especially significant for basic research
pertaining to metastasis as well as drug development. To
further complicate matters, the recent appreciation of genetic
alterations and biomarker expression, for instance KRAS,
within tumors means a single biopsy sample is no longer
sufficient [9]. Henceforth, detecting and analyzing these cells
on a sample of blood may shed new light on circumvents
clinical need to improve therapeutic efficacy as well as the
overall patient survival rate. Despite its high potential in
cancer treatments, the detection of CTCs from whole blood
sample is particularly challenging due to their extremely rare
presence, which is only 1 to 10 CTCs per billion normal
blood cells in patients with advanced cancer. Besides, the
large morphological variability among CTCs has imposed
technical challenge to isolate the whole population, where
sophisticated algorithms are required to identify the CTCs.
Aforesaid, CTC counts are associated with patient prognosis.
Thus, a highly sensitive detectionmethod is vital to accurately
characterize and enumerate the CTC.
Numerous methods have been employed and discussed
in the literature for CTCs separation. To date, the benchtop
device developed by Veridex is the sole system approved
by United States Food and Drug Administration for the
clinical monitoring of CTC counts in patients withmetastatic
breast, colon, and prostate cancer.Through this approach, the
CTCs are distinguished from other blood cells based on their
immunoaffinity properties. The selection is carried out by
using antibodies coupled with magnetic beads, targeting the
tumor-associated antigen onCTCs surface (EpCAM,CK, and
CD45).This system is proved to have sensitivity of 87.7%with
the capability to detect of approximately 5 CTCs per 7.5mL of
whole blood. Despite the proven clinical ability of this system,
a few data have been published, concerning the inconsistently
markers expressed by all tumor cells. Noteworthy, EpCAM is
not expressed in all histological tumor types and thus might
result in false-negative/positive result and limit the purity of
the enriched CTC fraction. Using affinity capture method
in macroscale analytical system will also lead to permanent
attachment of target cells to marker protein on CTC. Con-
sequently, the downstream options for the extraction and
subsequent characterization of CTC will be narrowed down.
In addition to immune-affinity based separation, in fact, a
large panel of approaches for CTC isolation that are indepen-
dent of cell surface antigens have been developed on the basis
of its physical properties. The majority of the physical meth-
ods for CTCs isolation exploit the differences in mechanical
and physical properties, including cell size, deformability,
electrical polarizability, and magnetic susceptibility. In con-
trast to the immune-affinitymethodwhere epithelial antigens
are needed to mediate the intercellular adhesion, this tech-
nique is label-free. Therefore, the interference such as sample
contamination due to the tagging molecules can be avoided.
Since CTCs are unmodified by physical separation, cells iso-
lated using these methods are compatible with wider range of
analyses, including those requiring viable cells. Consequently,
it allows large range of molecular biological analysis of CTCs
to be implemented and thus provides clinician with further
insight into CTCs role in tumor formation.
In this paper, we will present an overview about the pot-
ential application of benchtopCTCdetection device based on
their physical properties in clinical oncology. Both detailed
description of various separation principle and comparisons
based on separation metrics such as efficiency, viability, and
throughput are included in this review. Additionally, the
challenges faced by each technique will too be succinctly dis-
cussed.The readers are encouraged to read the original papers
for additional details.
2. Comparison of Biophysical and
Biomechanical Properties between
CTCs and Normal Blood Cells
According to most CTCs histological study, researchers have
observed changes in cell cytoskeleton contents and their
cytoskeletal structures as it progresses toward a cancerous
state. For instance, CTCs are found to have greater nuclear to
cytoplasmic ratio, larger size, and distinct nuclear morphol-
ogy in contrast to the normal cells. In fact, these cytoskeletal
changes have resulted in changes in the overall mechanical
properties of cells. Computational mathematical model con-
ducted by Rejniak has demonstrated the insight of CTC’s
deformation trajectories within blood vessel [36]. His find-
ing highlighted that CTCs’ cellular biomechanics such as
deformability played an important role in metastasis. As an
example, in order to invade distal sites, the stiffness of CTCs
cytoskeleton is modified subsequently in a very dynamic way
so that it could squeeze across small spaces in extracellular
matrix and endothelial cell-cell junctions as well as circulat-
ing through the small capillaries. In order to successfully per-
form the metastatic cascade, the CTCs cell membrane must
withstand hemodynamic forces and overcome the effects of
fluid shearswithin the blood vessel. Consequently, it alters the
conservation of membrane structure, which in turn affects
the surface charge (electrical charge), in contrast to normal
blood cells [37]. These distinct physical differences in size,
deformability, and electrical properties between tumor cells
and blood cells have allowed researchers to employ them
as physical-based CTC detection method. The physical and
biomechanical properties of CTCs will be briefly discussed
in the following section.
2.1. Size. Inmorphological studies, themeasurementmethod
such as flow cytometry [38], blood smear, or detailed exami-
nation with microscopic study are broadly employed to ana-
lyze the cell size of CTCs in comparison to normal cells.
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The size measurement of cell is normally interpreted in cell
area, length, width, and shape features. Despite the differ-
ences in these measurement methods, they provide similar
quantitative value for both CTCs and normal blood cell
measurement, respectively. For example, normal human
erythrocyte, also called red blood cells (RBC), is found to
have biconcave disks with the diameter of approximately 6
to 8𝜇m [38–40]. White blood cells (WBC) are derived into
two groups, which are granulocytes and agranulocytes. The
granulocytes such as neutrophils and eosinophils are typically
of 12 to 15 𝜇m in diameter [41]. Meanwhile, agranulocytes
such as lymphocytes vary widely in size where the small
lymphocytes are 7–10 𝜇mwhile large lymphocytes are appro-
ximately 14–20 𝜇m in diameter. Monocytes are among the
largest leukocytes with a diameter of 15 to 25 𝜇m in blood
smears [38, 41–43]. In contrast to the mentioned blood cells,
the size of CTCs reported in the literature is generally larger
than normal blood cells, ranging from 17𝜇m to 52 𝜇m. The
clinical relevance of this taxonomy has been investigated and
confirmed by many research groups [44–47]. For instance,
few groups of study done on breast cancer patients had found
that CTCs showed significant variability with consistent
elongated shape and most of them were larger compared to
the leukocytes surrounding it [45, 48, 49]. Similarly, in a
study of patient with prostate cancer, Park et al. had reported
that highly ruffled surface membrane of CTCs had created
an excess of membrane surface area. As a result, majority of
CTCs have larger size in contrast to normal blood cells [50].
The observation of differences in size of CTCs in comparison
to other blood cells has motivated several devices to exploit
it as their primary label-free separation criteria. Despite the
fact that CTCs have larger cells compared to other blood cells,
there is a significant overlap in size of CTCs and leukocytes
that might hinder size-based separation process. The calcu-
lation conducted by Marrinucci et al. had concluded that
CTCs are highly heterogeneous including both high and low
nuclear to cytoplasmic ratios whichmight cause them to vary
in size [51]. Therefore, proper consideration in the proposed
device design and their operational parameters are needed for
high efficiency isolation-based-size method.
2.2. Deformability. The measurement of tumor cells defor-
mabilitymainly refers to viscoelasticity, a property ofmaterial
that falls into a category between that of an elastic solid and a
fluid. Cellular viscoelasticity arises from the combination of
highwater content conflatedwith a polymerized cytoskeleton
structural matrix. In microrheological studies, this mechan-
ical property is governed by cell surface interactions as well
as normal force exerted by the cell on the capillary wall
under physiological conditions and in response to external
signals. Various approaches were employed in vitro to study
thesemechanical changes, with techniques ranging fromcon-
ventional atomic force microscopy (AFM) [52–55], micro-
pipette aspiration (MPA) [56, 57], and magnetic twisting
cytometry to more recently tailored automated systems such
as microfluidic resonator [58] and inertial focusing method
[59]. The advantages and drawbacks of these techniques
have been discussed in detail [56, 60]. In fact, the tradeoff
between experimental automation and complexity ofmeasur-
able properties method (such as AFM andMPA) has resulted
in most measurement lacking throughput and precision.
Despite of their shortcomings, several consistent cell
mechanical behaviors are observed across multiple studies
where cancer cell lines are employed. Measurements of the
cellular mechanical behavior are frequently lumped into a
single universal parameter: Young’s modulus. It quantifies
the measurement of cancer cell stiffness which is intimately
linked with the distribution of actin network within cell
cytoskeleton. Various studies have compared the viscoelastic
properties of cultured cancer cells and blood cells using
AFM technique.The stiffness ofmetastatic cells was generally
found to be lesser (Young’smodulus of 3.7 kPa–150 kPa) com-
pared to normal blood cells (Young’smodulus of 0.2 kPa) [53–
55, 61]. This statement is concurred with a recent study con-
ducted by Byun et al. [58], whereby a suspended microfluidic
resonator is used to track the cell’s velocity as the blood sam-
ple spikedwith human lung cancer cells traverses through the
constriction region of the device. Their result has indicated
that lung cancer cells took a shorter time to deform and trav-
eled through the integrated constriction in the microfluidic
channel, compared to normal blood cells, thus suggesting that
cancer cells exhibit high cytoskeletal deformability [58].
While researching the viscoelasticity properties of tumor
cell in the context of metastasis, various studies have exp-
ressed the strong correlation between cell deformability and
cell malignancy. For instance, Mak and Erickson [56] and
Mohammadalipou et al. [57] have measured the mechanical
properties of both metastatic and benign breast cancer cell
lines withMPA, whereby the metastatic cancer cell lines were
found to have longer aspiration length which in turn resulted
in higher Young’s modulus measurement value (calculated
from the pressure slope versus aspiration length graph).
Likewise, the AFM-based analysis performed by Chen et al.
across prostate cancer cells lines (LNCap-AD, LNCap-AI,
and PC-3) indicated that the noncancerous BPH-1 cells were
found to have the least elasticity with Young’s modulus of
3.7 kPa, whereas the highly metastatic PC-3 cells (Young’s
modulus of 0.13 kPa)were almost 30%more elastic in contrast
to BPH-1. Noteworthy, Young’s modulus values described in
these experiments were formulated based on the cell elastic
properties, using Hertz model, which was used to describe
the physical relationship between the applied force and the
cantilever deflection on indentation. Apart of cultured cell
lines, Chen et al. also havemeasured Young’s moduli of CTCs
isolated from blood of patient with castrate-resistant prostate
cancer and bone metastasis. When a comparison was made
between CTCs and prostate cancer cell line, the values of
Young’s moduli obtained for CTCs (ranged from 0.23 to
1.1 kPa) were similar to that of PC-3, thus inferring they are
metastatic. In accordance with the relationship between cell
malignancy and deformability, investigation of ex vivomech-
anical changes of cancer cells was conducted by Cross et al.
[62]. Their study has reported the stiffness of live metastatic
cancer cells taken from pleural fluids of breast cancer patients
(Young’s modulus of 0.53 ± 0.10 kPa) that was 70% lower, in
contrast to the benign cells reactive mesothelial cell (1.97 ±
0.07 kPa) within the same fluid samples. This statement is in
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agreementwith study demonstrated byChen et al. on prostate
cancer cell line, as mentioned previously.
The brief finding presented here indicates that cell
deformability can be considered useful parameters to reflect
a histological background of a cell and distinguish between
nonmetastatic and metastatic cells.
2.3. Electrical Properties. Studies of the cell morphology have
provided fundamental statement that the cell membrane
selective permeability is controlled by electrical charges [37,
63]. The different concentrations of molecules on inner
and outer sides of the membrane have created an electrical
potential across themembrane.Thework by Becker indicated
that the major charge carriers of biological cell membrane
were negative at physiological pH, such that the healthy living
cells were found to have a membrane potential within the
range of −60 to −100mV [64–68]. The negative sign of the
membrane potential indicated that the inner surface of the
cell membrane is relatively lower than the immediate exterior
surface of cell membrane [69]. However, the cell membrane
charge was found to be altered during tumorigenesis due to
its abnormalmetabolic transformation [37].Therefore, inves-
tigation of cell electrical behavior when they are subjected to
an electric field can furnish information for the purpose of
cancer cell isolation.
In literature, two technique are typically used to measure
electrical properties of cells, such as impedance spectroscopy
[70] and electrorotation (ROT) [71]. Both methods provide
quantitative information of inherent electrical and dielectric
properties of cells; such asmembrane capacitance,membrane
resistance, cytoplasmic conductivity and permittivity. For
impedance spectroscopy, it is employed by researches to
measure cell suspension dielectric properties as a function
of frequency, giving a population averaged value for the
cell properties. Meanwhile, measurement for electrorotation
is performed on single cell level, which is located at the
center of four electrodes. A 90-degree phase excitation signal
is applied to the electrode and the cell rotation speed is
recorded. Depending on the frequency of ROT excitation
signal, the cells will exhibit vary rotation speed based on their
cytoplasmic conductivity and permittivity.
Becker et al. has investigated the differences in dielec-
tric properties of metastatic human breast cancer cell
line MDA231, erythrocytes and T lymphocytes with ROT
method. The result showed that the metastatic human breast
cancer cell line MDA231 had higher membrane capacitance
(26 ± 4.2mF/m2) than T lymphocytes (11 ± 4.2mF/m2) and
erythrocytes (9 ± 0.8mF/m2) [71]. Meanwhile, Qiao et al.
presented an investigation of impedance for cell suspensions
for four breast cell line, namely MCF-7 (early stage cancer
cell), MDA-MB-231 (invasive cancer cells) and MDA-MB-
435S (late stage cancer cells), with impedance spectroscopy
measurement technique [70]. In their study,Maxwell-Wagner
theory was employed to analyze the electrical parameters of a
single cell based on the average result obtained from the exp-
eriment. The result uncovered that different stages of cancer
breast cells can be distinguish by the conductivity presented
by each cell. For instance, early stage cancer cell, MCF-7
had higher whole cell conductivity and cytoplasmmembrane
capacitance (value of 5.58mS/cm and 3.94 𝜇F/cm2) in con-
trast to late stage of cancer cell, MDA-MN-435s (value of
3.97mS/cm and 1.10 𝜇F/cm2). Based on the outcome of these
researches, we are clearly informed that each cell line had a
specific electrical signature which could be utilized for iden-
tification of cancer cells and differentiation of the pathology
stages of malignant cells. The technique which employed
the principle of cell’s membrane electrical differences for
separation is named as electrokinetic (e.g., dielectrophoresis).
Its details will be discussed in the next section.
3. Benchtop Technologies for CTCs Isolation
In general, the physical cell-based isolation tools that resear-
chers developed for the purpose of benchtop CTCs detection
can be classified into two types: the conventional macroscale
analytical system and microfluidic devices. For macroscale
system, it mainly relies on large laboratory equipment, with
the usage of a few milliliters (mL) of cell suspension (e.g.,
centrifuge). Since these devices often require a large number
of cells from human and animal models, it reduces the
likelihood for the patient and physician to receive the results
quicker, which causes them rarely to be used in point-of-
care application. To overcome the limitations imposed by
macroscale system, vigorous efforts have been undertaken
to develop robust laboratory test over the past decades. As
a result gained from the advances of micro- and nanofabri-
cation approaches, there is a growing trend towards carrying
out microscale laboratory work, on a scale of one-tenth to
one-thousandth of that macroscale system. These miniatur-
ization reaction platforms are termed as microfluidic devices.
In contrast to macroscale system, the use of microfluidic
device has offered various advantages such as scalable, shorter
analysis time and smaller sample size. Furthermore, this
technology enables the actuation of fluid and manipulation
of bioparticles at microscale. Such feature is especially impor-
tant for CTCs research in considering the rare presence
of CTCs within the blood, as mentioned previously. Both
macroscale and microfluidic techniques employed for phys-
ical based CTCs detection will be discussed in detail in next
section.
3.1. Macroscale CTCs Detection System
3.1.1. Density Gradient Centrifugation. Separation of cellular
constituents within blood is widely achieved by density
gradient centrifugation.This technique uses centrifugal force
to separate the cells based on their sedimentation coefficient
differences. According to Stokes law of sedimentation, the
rate of a particle’s sedimentation is directly proportional to
its size and density and relative to the density of suspension
fluid. As the mixture of diverse cell sample is subjected to
centrifugation, the different types of cells will pass through
the density gradient at different rates depending on their
density, resulting in distinct zones appearance (Figure 1).
The heavier particles such as RBC and neutrophils (density
of >1.077 g/mL) will appear at the bottom while the CTC,
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Figure 1: Principle of density centrifugation separation method. Sample is layered on top of a density gradient, Ficoll. Under centrifugal
force, particles move through the medium and density gradient and be suspended at a point in which the density of the particles equals the
surrounding medium.
plasma, and mononuclear (density of <1.077 g/mL) will
remain at the top as buffy coat [72].
In fact, centrifugation has been employed as early as 1950
by Fawcett et al. to separate cancer cells from peritoneal fluid
[73]. A floatation medium is developed in their study to
optimize the cell separation into its distinct layerwithout sub-
jecting the particle to high osmotic or ionic stress. Although
this research provided a favorable result such that four layers
(which consist of saline, malignant cells, albumin solution,
erythrocytes, and leukocytes) are formed in accordance with
the particles density, and the use of albumin as floatation
mediumwas costly and uneasy to be prepared [73]. Following
this research, another density gradient centrifugationmethod
is set forth by Seal for CTCs isolation in which silicon
blending oil was used as floatation solution. In his study,
cancer cell is successfully detected in 53% gastrointestinal
tract cancer patient samples and 33% breast cancer patient
samples [74]. Although both studies showed low separation
efficiency, they have uncovered the importance of the use of
gradient medium in centrifugation process. Consequently, it
has led to escalating efforts in search of gradient media mate-
rial which provided high separation efficiency. Nowadays,
density centrifugationmedia such as Percoll, Ficoll-Hypaque,
and OncoQuick are more widely employed in preclinical and
clinical cell centrifugation researches.
Ficoll-Hypaque is a type of sucrose polymer with high
synthetic molecular weight. Its gradient media is mainly used
in the isolation of human mesenchymal stem cells (hMSCs)
[75]. Despite its popularity, various studies reported that this
method has low CTCs separation efficiency. Considerable
numbers of tumor cells and hMSCs are found to accumulate
in the lower fraction instead of preferable upper fraction after
density gradient separation. For instance, study conducted by
Lara et al. indicated that the use of Ficoll-Hypaque gradient
medium had mononuclear cells recovery of 57% [26]. Sim-
ilarly, when this gradient medium is employed by both van
Beem et al. and Aktas et al. for bone marrow mononuclear
cell enrichment process, the investigated cell recovery rate is
between 15% and 30% [76, 77]. They also highlighted that
both cell load and individual harvesting techniques have
great impact on the centrifugation performance with Ficoll.
Further study done by Ahmadbeigi et al. and Po¨sel et al. has
suggested that such an excess cell loss during Ficoll density
gradient centrifugation is a consequence of density medium-
related cytotoxicity [75, 78].
Meanwhile, Percoll density gradient media is made of
colloidal silica particle suspension. Unlike Ficoll-Hypaque
mediumwhich is in ready-to-use form, the osmolality of Per-
coll medium must be adjusted with saline medium to make
it isotonic with physiological salt solution. Such a premade
gradient allows it to cover a wide density range for isopycnic
banding of all biological particles of interest, such as various
cells andmicroorganism. In the literature, Ellis et al. reported
the use of Percoll has obtained more than 90% purity for
the gradient that yielded populations of mononuclear cells,
neutrophils, and platelets [79]. However, this research is in
contradiction with recent study done by Chang et al. on
relative isolation efficiencies of both Percoll medium and
Ficoll medium. For instance, Ficoll density centrifugation
shows high number of isolated mononuclear cells (25.3 ±
8.9× 107 cells) compared to thosewith Percoll (13.6± 6.6× 107
cells) [80]. Yet, both Percoll and Ficoll share the same pitfall
such that the blood sample tends to mix with the gradient
media if the centrifugation did not perform immediately after
applying the sample to the gradient media. Such a condition
is undesirable as it will cause a reduction of therapeutically
relevant CTCs cell populations.
The ongoing study to increase the CTCs recovery rate,
focusing on reducing the cell loss and contamination, has led
to the OncoQuick centrifugation system. It is a novel tech-
nology in which a porous barrier is nestled within the 50mL
centrifuge tube to prevent the lower compartment (separa-
tion medium) from mixing with the blood sample, prior to
centrifugation. Following buoyant density gradient centrifu-
gation, the cells will be separated and pass through the barrier
according to their different buoyant densities. As previously
mentioned, RBCs and the granulocytes have higher buoyant
densities in contrast to other blood cells. Thus, they are
partitioned below the porous barrier.Meanwhile, CTCs along
with the mononuclear lymphocytes will remain above the
porous layer, which allow them to be easily accessible for
subsequent collection and analysis of CTCs. In the literature,
OncoQuick has showed a significant improvement in CTCs
isolation over centrifugation based on Ficoll and Percoll. For
instance, study conducted by Gertler et al. indicated that
OncoQuick has higher relative tumor cell enrichment than
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Ficoll density gradient centrifugation when the separated cell
fractions were evaluated with flow cytometry. Despite having
low cell fraction (9.5 × 104 mononuclear cells) in contrast to
1.8× 107 cells by Ficoll, the tumor cell recovery rate is between
70% and 90% for both systems [81]. Similarly, Ko¨nigsberg
et al. have applied the same technique to isolate CTCs from
blood sample of 26 metastatic breast cancer patients. The
CTCs were spotted in 69.2% of blood samples [27].
3.2. Microfluidic Device
3.2.1.Microfiltration. Microfiltration is a technique of flowing
cell sample through an array of microscale constrictions in
order to capture target cells based on size or a combination
of size and cell deformability. Several microfilter designs are
developed in the literature for benchtop CTCs separation,
varying in terms of their blood passing capability and trap-
ping efficiency. The microfilter developed for the CTCs sepa-
ration can be categorized based on their geometrical design.
Among them,membrane, weir, pillar, and packed bead-based
microfilters are frequently discussed in the literature.
For membrane microfilter, it consists of a semiperme-
able membrane perforated with a 2D array of small holes
(Figure 2(a)). Such filters are commercially available in differ-
ent pore size and most of the reported membranes for CTCs
separation have pore sizes of 6–11 𝜇mdiameters. Noteworthy,
a pore size around 8 𝜇m in diameter is proved to be optimal
for CTCs retention [82]. Since the pore size can be precisely
selected at dimensions commensurate with blood cell exclu-
sion, membrane based filtration is suited for microfluidic
blood enrichment application. In early research stage, the
dead-end flow configuration is commonly employed for
microfiltration sample advection such that the blood flow
is perpendicular with membrane surface. Particles smaller
than the pore sizes will pass through the membrane and
vice versa for the larger particle. Despite its simplicity in
implementation process, study conducted by Shiau et al.
showed that the deposited layer of trapped cells on the
membrane in the late filtration period has governed the
buildup of filtration resistance. As a result, the efficiency of
device to isolate cultured cancer cells from the whole blood
sample is reduced [83]. To overcome these issues, a 3Dmem-
brane microfilter which consists of two-layer membrane was
proposed by Zheng et al. [11]. Both the top and bottom layers
have pores defined by microfabrication and the cell capture
is realized by the gap between both layers. The important
feature of this design is that the larger pores (9𝜇m diameter)
located on the top layer of microfilter patch are aligned with
the center of corresponding hexagon pattern of the smaller
pores (8 𝜇m diameter) on the bottom later. When the CTC
cultures from human blood sample flow through the 3D
membranemicrofilter, the smaller cell such as RBC andWBC
will be easily traversed through the gap; meanwhile, the
tumor cells are trapped in the pores of top membrane. The
bottom membrane will provide direct force on the trapped
tumor cells to counter hydrodynamic force in opposite
direction. Subsequently, the concentrated tension stress on
cell plasma membrane can be greatly reduced in contrast to
the conventional membrane microfilter. This device has
demonstrated capture efficiency of 86%, with a throughput
of 3.75mL/min [11]. Very recently, Zhou et al. have reported
a new design of 3D microfilter membrane, as illustrated
in Figure 2(b) [13]. This device has fundamentally different
structure and filtration principle in contrast to Zheng et al.
For instance, the pores on the top membranes are five times
larger than the pores (8 𝜇m diameter) on the bottom mem-
branes. Consequently, the captured tumor cells will wedge
into the gap between the top and bottomofmembranes. Since
this device features separable 3D membrane, the captured
tumor cells from the healthy donor blood sample spiked with
multiple cancer cell line can be accessed by separating the
two layers membrane. A capture efficiency ranged from 78
to 83% and cell viability of 71 to 74% is reported. Leveraging
the advantage of two-layer membrane microfilter, Yusa et
al. have developed a palladium filter unit in which a filter
cassette (consists of two-layer membrane, with 8 𝜇m sized
pores in bottom layer and 30𝜇m-sized pores in upper layer) is
sandwiched in between the upper and lower rings, as shown
in Figure 2(c) [12]. In contrast to the previously discussed 3D
membrane microfilter in this paper, this device allows only a
relatively low flow rate (2.4mL/min). A further analysis with
computational modeling software has indicated an inverse
correlation between the numbers of pores with the filter’s flow
rate. The recovery rate of spike breast and gastrointestinal
cancer cells by this 3D palladium device is sufficiently high,
which is>85%.Although these devices are reportedwith high
capture efficiency of CTCs, low enrichment factor is showed
across multiple studies. To enhance the enrichment factor as
well as eliminate the resistance buildup around membrane
microfilter, Lu et al. have proposed 2D membrane slot filter,
as depicted in Figure 2(d) [28]. Compared to the commonly
employed circular pores, slots allow easier deformation of
blood cells in their longitudinal direction, which facilitates
easier passage of normal blood cells. Furthermore, the large
fill factor of cell also reduces the buildup of flow resistance
during filtration and thus minimizes the forces exerted on
cells. Consequently, a high viability (>90%) andhigh recovery
rate (>90%) of isolated cancer cells are reported. Apart of
changing the architectural design of membrane microfilter,
a crossflow configuration is introduced to resolve the prob-
lems of pressure buildup during membrane filtration (see
Figure 2(a)). Unlike dead-end flow configuration, its filtered
flow is parallel to the filtration surface. Membrane micro-
filter developed by Adams et al. using this principle has
demonstrated the ability to capture more than 98% of MCF-
7 cancer cells from a diluted 7.5mL blood sample, given that
the membrane consists of uniform patterned distribution of
>160000 pores with diameter of 7 𝜇m [10].
Apart of membrane basedmicrofiltration, weir-type stru-
ctures are typically employed as filter element across the
width of the microfiltration chip. It involves an individual
barrier obstructing the flow path to trap most of the CTCs
from the blood sample while WBC and RBC will pass
through the narrow slit located on the top of barrier as shown
in Figure 2(e). In the literature, such a device is commonly
used to isolate white blood cells from the whole blood sample
[84–86]. Up to themoment, Chung et al. are the first and only
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Figure 2: Schematics of various microfiltration mechanisms: (a) membrane microfilter (reproduced with permission from [10], copyright
2014, The Royal Society of Chemistry). Its fluid flow configuration can be further categorized into two types, which is dead-end filtration
and crossflow filtration. (b) 3D membrane microfilter with key geometrical parameters labelled. The smaller cells can easily traverse through
the gap while the large cells (e.g., tumor cells) will be trapped. Two types of force are exerted in the trapped cell such that force is caused by
hydrodynamic pressure from top and supporting force from bottom membrane (reprinted by permission from Macmillan Publishers Ltd.:
ScientificReports [11], copyright 2015). (c) 3Dpalladiummembranemicrofilter cassette and its SEM images of filter (reprintedwith permission
from [12], copyright 2014, PloS One). The cross-sectional view showing tumor cells will be trapped within the gap of the membranes [13]. (d)
Membrane slot filter design. (e)Weir-type filter (adapted with permission from [14], copyright 2001, American Chemical Society). A silt-type
structure is fabricated within the flow channel to improve the target cells retention.The smaller weir gap is designed to allow human RBC and
plasma to pass through while retaining CTCs. (f) Cross-sectional view of diagonally weir-type filtration (reproduced with permission from
[15], copyright 2012, John Wiley and Sons). (g) Bead-packed based filtration. The microchannel entrance is blocked by packing large sized
beads. Different bead sizes were used to implement a blood/plasma separator at the inlet of the microchannel. Subsequently, when whole
blood was dropped into the inlet of the microchannel, the structure was allowed for the capillary flow of blood through the hetero-packed
beads. During this movement of blood, the RBC will pass through small pores while big sizes cells such as CTCs will be blocked from flowing
into the channel (reproduced with permission from [16], copyright 2012, The Royal Society of Chemistry).
groupwhich employedweir-basedmicrofiltration to perform
CTCs isolation from the unprocessedwhole blood cells.Their
proposed weir-type device featured a barrier with height
of 10 𝜇m and 80 𝜇m in width across the main channel at
a small angle of 10∘ (Figure 2(f)), which effectively allowed
the passage of 99% of blood cells (erythrocytes, 6–8𝜇m;
leukocytes, 8–10𝜇m) that passed through the barrier while
impeding the CTCs (>10 𝜇m). This strategy is found to
achieve high enrichment ratios (>2 × 104) and recovery rates
(>95%) at the flow rate of 20mL⋅hr−1 [15]. In contrast to weir-
type structure, the pillar structures are much more widely
used in CTCs isolation [29, 87–89]. Similarly, to the weir-
based microfilter, the layout of this device consists of arrays
of pillar structures within themain flow channel to allow cells
smaller than the slit to pass through it. Using this technology,
Lin et al. (2010) have demonstrated recovery rate of >90% in
57 blood samples from cancer patients [29].
Besides, the performances of bead-packed based filtration
for CTCs isolation process too are discussed in the literature.
Such a method is typically incorporated with the capillary-
driven analysis systems, whereby a batch of uniform (diam-
eter of 45 𝜇m) [30] and nonuniform beads (diameter ranged
from 100 𝜇m to 15 𝜇m) [16] are packed into a chamber and
act as the filter element (Figure 2(g)). Subsequently, when the
blood is channeled into the filtration chamber inlet, blood
cells such as RBC and WBC are allowed to flow through the
packed-bead whereas CTCs will be immobilized within the
packed bed. To prevent the cells from binding to the beads,
protein-blocking solution is sequentially introduced before
the experiment to develop hydrophobicity on the channel and
bead surface. According to study conducted by Arya et al.,
the overall CTCs’ capture efficiency for packed-bed based on
polystyrene and chitosan beads was lower (varied between
21% and 40%) in contrast to filtration generated by mem-
brane, pillar, and weir-based structure.
In general, themain advantages ofmicrofiltrationmethod
lie in its simplicity and its capability to obtain the fractiona-
tion of whole blood in a single pass. Additionally, it allows
for the counting of CTC per milliliter of blood andmaintains
cell integrity for CTC detection and further characterization.
To achieve high purity and recovery rate with this device,
two parameters such as the flow rate of the fluid and the
cross section of the pores or the gap dimensions require
proper consideration.The fluid flow rate will impact the force
applied to each cell as it is deformed through a constriction,
whereas the pores or gap dimensions determine the size and
deformability of target cells that can be captured by the
filter. The significance of their role in filtration is further
highlighted whenmathematical study conducted byMa et al.
discovered the direct correlation between cell lysing and
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Figure 3: Illustration of (a) an acoustophoresis device and (b) the particle gradient within the microchannel cross section after passing over
the transducer (adapted with permission from [17], copyright 2007, American Chemical Society).
the applied mechanical trauma (e.g., shear force), such that
membrane area with increment exceeding 3% will result in
permanent damage on the cells [90]. Since the effectiveness
of the isolation mechanism is controlled by the tailored
gap and pores dimensions, a few problems have aroused.
Firstly, the mechanical filtration system which separates cells
based onmicrofilter’s geometrical differences is not universal.
Variation in microfilter architecture is required when the size
of target cells is changed. Besides, the heterogeneity of CTCs
has caused the smaller cells which exhibit carcinoma char-
acteristic from being detected by this device. Consequently,
a loss in the target cells for further downstream analysis
is feasible. Moreover, the high concentration of blood cells
can easily cause clogging of microscale constriction or filter
structure designed for cell sorting in microfluidic devices,
compromising their performance for applications involving
whole blood samples. Noteworthy, CTCs are needed to
be removed from membrane microfilter to perform down-
stream analysis (such as PCR-assays and cytomorphology).
However, CTC handling such as aspiration and ejection of
single cells into the PCR tube by micromanipulator is time
consuming. Furthermore, the nontransparent material of
certain membrane microfilter has resulted in the need to
use upright fluorescence microscopy rather than the usual
inverted fluorescence microscopy for manipulation of CTC.
3.2.2. Acoustophoresis. Acoustophoresis is the separation of
particle using high intensity acoustic waves. Its device con-
sists of interdigitated piezoelectric transducers, which are
employed to generate acoustic standing wave. When the
cell suspension is subjected to the acoustic field, cells will
experience acoustic force. Depending on the cell density
and the difference of compressibility properties between cell
and the surrounding fluid, this force can vary by orders of
magnitude which in turn translates cells toward the pressure
nodes (point where the periodic pressure variations are zero)
or antipressure node (point with maximum acoustic pres-
sure). If the flow rate, acoustic force, and particle mixture are
correctly balanced, particle gradient will be developed across
the channel at its end as illustrated in Figure 3. By introducing
multiple outlet branches into themicrofluidic design, the cells
can be separated and guided toward their respective outlet.
Following the acoustophoresis success in RBC sorting by
Petersson et al. [91], the differing of acoustophysical prop-
erties of CTCs is investigated as the principle for separation
from other blood cells. Up to the moment, there are only two
groups that have published their work on the performance
of acoustophoresis in preclinically CTCs separation. A first
effort to capitalize on this aspect was reported by Augusts-
son’s group. They have presented an acoustophoresis device
with trifurcation inlet and outlet to separate three different
prostate cancer cell lines (DU145, PC3, and LNCaP) from
no-cancer control subjects’ blood sample spiked with the
mentioned cancer cells [32]. As previouslymentioned, cancer
cells have higher density and compressibility in contrast to
normal cells. Consequently, they are found to move toward
and align themselves in the center of the channel (pressure
node), while normal blood cells can be detected near the
channel wall (antipressure node). To minimize the influence
of parabolic flow profile, which may otherwise affect the
efficacy of tumor cells separation from WBC, method of cell
prealignment on paraformaldehyde (PFA) fixed cells before
acoustophoretic separation is introduced into their device
architecture. In contrast to typical nonprealignment method
[17], an improvement in cell separation is observed, yielding
tumor cells recoveries of 87 and 83% of DU145 and PC3 cells,
respectively, with regard toWBC suppression of 99.3%.When
the device performance on nonfixed sample is evaluated,
changes in intrinsic acoustic properties are experienced by
the WBC such that the WBCs are detected to have high
depletion rate at low acoustic energy. However, the tumor
capture efficiency is virtually unchanged in contrast to PFA
fixation sample; that is, the device shows an increase in
separation efficiency for both samples in accordance with
acoustic energy. For instance, the average central outlet recov-
ery of DU145 cells (nonfixed sample) was 85.4% and 96.6%
at 𝐸ac of 120 J/m
3 and 188 J/m3, respectively. Meanwhile, for
nonfixed method, the average DU145 cell recovery was 36.1%
at 𝐸ac of 66 J/m
3 and 83.7% at 𝐸ac of 103 J/m
3. Additionally,
this research also highlights that no significant difference in
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cell viability between acoustophoresis treated and untreated
cells was found for both types of sample. This statement is
concordant with study done by Burguillos et al. [33], focusing
on the effect of acoustophoretic force on prostate tumor cell’s
viability and proliferation. Changes in mitochondrial poten-
tial aswell as cell function via their inflammatory response are
selected as themeasurement parameter for cell viability.Their
experimental result depicted no changes in mitochondrial
potential due to acoustophoresis. Also, the cell properties
are unaltered after acoustophoretic processing as measured
by cell turnover assays as well as inflammatory cytokine
response up to 48 hours following acoustophoresis [33].
Although both studies suggested that the microchannel
acoustophoresis can be used for effective CTC’s detection,
this technology is still under preclinical development stage.
The main challenge for acoustophoretic microfluidic device
to be clinically relevant is that the current system is unable to
generate data for blood samples containing much lower con-
centrations of cancer cells. Furthermore, in accordance with
most microfluidic systems that handle particles, acousto-
phoresis systems are also challenged by clogged systems and
occluded channels when the cell concentration is increased.
Such a condition can be countered by extending the length of
chip, the optimization of flow rate within the microchannel,
and the increase of the acoustic force. Although the increase
of acoustic force can result in significant improvement of
tumor cell recovery which is low in concentrations, Petersson
et al. [17] have reported that the acoustic force cannot be
increased without limit as high acoustic pressure can cause
biological cells lysis. Henceforth, there is a need for acoustic
radiation forcemodel which can be used to calculate the force
magnitude to be modified to accurately represent the setting
in a microfluidic chamber.
3.2.3. Dielectrophoresis. Dielectrophoresis (DEP) is one of the
phenomena commonly grouped as part of AC electrokinetic.
It refers to the particles motion under nonuniform electric
field. Depending on the conductivity and permeability of the
cells as well as its suspending medium, the cells can exhibit
attractive and repulsive response at a given electric field fre-
quency. For instance, if the particle is more polarizable than
its surrounding medium, the particle will experience a net
force toward the high electrical field gradient. Such a condi-
tion is termed as positive-DEP (pDEP).Meanwhile, negative-
DEP (nDEP) happenswhen the surroundingmedium ismore
polarizable than the particle which causes the particle to
move toward the low electrical field region. As alluded in
previous section, CTCs feature high surface areas which in
turn give them larger capacitance per unit area in contrast to
the normal cells. These factors have contributed to the dif-
ferences in cell dielectric phenotypes, thus directly affecting
their motion under electric field in contrast to the normal
cells. The carcinoma cells will exhibit nDEP and vice versa to
the normal cells. In the literature, the benchtop DEP device
has been successfully used to isolate oral cancer [92, 93],
colon cancer [94], breast cancer [31], lung cancer, and prostate
cancer cells [95], with a recovery rate of 70–90%. Following
these successful separation and subsequent preliminary DEP
analyses of cancer cells, a multitude of DEP-based clinical
CTCs isolation studies are ensued.
In order to convey the proper control of DEP force on
blood sample, it is necessary for researchers to select or
develop appropriate microelectrode designs which fix their
studies requirements. For the existing DEP devices, the 2D
metallic microelectrodes with various geometries, such as
interdigitated [96, 97], castellated [98], curved [31, 99], spiral
[100], and ring shape [101], are normally patterned within the
chamber of microfluidic device to generate nonuniform elec-
tric field that is of desirable strength for the CTCs isolation.
These microelectrode designs are easily to be fabricated with
common lithograph technique. Nevertheless, they are com-
patible with on-chip analysis for continuous manipulation of
blood samples. However, there is a pitfall in this technique
such that electrical fields are found to decay exponentially
with the distance away from the electrode. It has caused
cancer cells away from the electrode less controlled by DEP
force. To circumvent these issues, Lewpiriyawong et al. have
suggested the use of 3D electrode deposited at the channel
wall to generate electrical field covering the whole volume of
channel, as illustrated in Figure 4(a) [18]. This configuration
has been successfully demonstrated for cell sorting in study
done by Wang et al. (2009) [102]. Their results show an
improvement of 15% in cell recovery rate in contrast to the
conventional microelectrode. However, due to its fabrication
complexity, such a configuration is yet to be tested with
CTCs. In the latest research, Huang et al. developed a
DEP-based technology known as contactless DEP (cDEP)
which replaced the metallic electrodes by fluidic electrode
channels (see Figure 4(b)) [19].The cDEP is capitalized on the
sensitivity of traditional DEP, while eliminating challenges
such as bubble formation, electrode delamination, expensive
fabrication, and electrode sample contamination.The experi-
mental results have indicated that the cervical carcinoma cells
are successfully isolated from the concentrated RBC with a
recovery rate of 64.5%.
The major advantage of DEP compared to other separa-
tion schemes is that the variability in the frequency response
of cells is selective enough for DEP microsystems to monitor
therapeutic efficacy and to account for constantly evolving
tumor phenotypes. However, some considerationmight need
to be taken into account during the design of DEP device
for blood sample. In practice, most of the reported on-chip
DEP separation microfluidic devices require the use of low
conductivity medium in order to generate pDEP force to trap
cell of interest. Noteworthy, blood is a very high conductivity
medium. As a result, it might cause cells to experience nDEP
most of the time and thus influence separation performance,
thus influencing the cell separation performance as well as
the purity output.Though Gascoyne et al. [96] suggested that
CTCs enrichment through blood dilution allowsDEPdevices
to have optimal recovery, Leu and Liao [103] have reported
that the actual extraction efficiency drops for 20% if the dilute
ratio 1 : 3 of whole blood sample was conducted. Despite the
use of nDEP that is able to levitate particles above the elec-
trodes and thus protects vulnerable biological particles from
high electric fields, RBC could also be irreversibly damaged
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Figure 4: Schematic of DEP cell isolation devices. (a) DEP microchip with 3D side wall microelectrode. By imposing an AC voltage on
the side wall microelectrodes, cells will experience repulsive (nDEP) or attractive forces (pDEP), depending on their relative polarizability
between cells and fluid (adapted with permission from [18], Copyright 2011, American Chemical Society). (b) DEP system with contactless
microelectrode. This method is capable of manipulating cells without direct contact between electrodes and sample. The schematic of cDEP
platform design is showed, such that the electrode is inserted into two conductive microchambers, and is separated from the microfluidic
chamber by thin insulating barriers. Consequently, cell adherance to the microchip can be prevented. To accumulate the target cell onto the
central microelectrode, a stepping electric field is generated such that the applied electric field is subsequently switched between the adjacent
electrode pair via relays. Cell which experienced pDEPwill be guided along the direction of stepping electric field toward the center of circular
electrode (adapted with permission from [19], copyright 2012, Journal of Medical and Biological Engineering).
as a means of cell rupturing if electric field much higher than
0.12MV/m is applied [104].
3.2.4. Hydrodynamic Sorting. Hydrodynamics is one of the
important forces that govern the behaviour of microfluidic
devices. Its fundamental concept is represented with Navier-
Stokes equation, which describes the motion of fluid sub-
stances at a given point in space and time. Since the build-
in-channels of microfluidic devices have the dimension of
less than 1mm, the flow generated within them is completely
laminar at Reynolds number below 2000. Reynolds number
(Re) is a dimensionless parameter representing the inertial to
viscous forces ratio in a flow. At this low Reynolds number,
a particle has been expected to follow fluid streamline,
superposed with its intrinsic Brownian motion due to their
differences in size and density [105]. By resorting to this
principle into the designated microdevice geometries, the
cell can be separated according to the different flow rates of
parallel fluid flow into the desired outlet. Such a technique
is termed as hydrodynamic sorting and it can be further
classified into 3 types, which are pinched flow fractionation,
deterministic lateral displacement, and inertia separation.
Pinched flow fractionation acts according to the Zwei-
fach-Fung effect, such that the blood cells are separated
through lateral migration due to the asymmetric bifurcation
of laminar flow [106]. Its microfluidic design features a main
channel with multiple narrow channels branching at the end
of pinch section, as showed in Figure 5(a). Such a channel
design has resulted in the difference in flow velocity as well
as particle volume fraction between the branches. Depending
on the sizes and density of the particle, they will be pushed
into specific flow streamlines following by separation. In
the literature, this method is not much exploited in CTCs
isolation. Geislinger and Franke are the first and only group
who demonstrated continuous separation of cultured can-
cer cells (MV3-melanoma cell line) and blood cells using
pinching flow as driving force [34]. The proposed microflui-
dic device worked at much lower Reynolds numbers (Re <
1) and an expansion with smooth broadening was added to
increase the absolute distances to facilitate the isolation. The
efficiency of 100% and medium purity of 66% are yielded
in blood suspension with 9% of haematocrit. Although the
result showed excellent cell viability, study has reported that
such a technique is more suitable in a dilute suspension of
blood sample. To improve the separation performance, this
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Figure 5: Types of hydrodynamic cell sorting: (a) Pinched flow fractionation. In both microfluidic design by (i) and (ii) Takagi et al. [20],
multiple branch channels with different channel dimensions were arranged at the end of the pinched segment, thus resulted flow rate
distribution to each channel was different. Cell would then enter into their respectively outlet in accordance to their size (Reprinted with
permission from [20]. Copyright 2005 The Royal Society of Chemistry.). As illustrated in (iii) [21], the smaller particle will closely follow
the fluid streamline and move toward the upper portion of the exit area, while the larger particles move closer to the center. This is due
to the smaller cells tends to move faster under hydrodynamic force which resulted them to press closer to the wall as the flow ratio increase
(Reprinted with permission from [21]. Copyright 2013, JohnWiley and Sons.). (b) Deterministic lateral displacement.The presence of array of
microposts (which each row of posts is slightly offset laterally with respect to the previous row)will cause the cells below critical hydrodynamic
diameters (such as WBC and RBC) to follow the streamlines cyclically through the gaps. Meanwhile, cell above critical hydrodynamic posts
such as CTCs will be moved by lateral drag into sequential streamline at each post (reprinted with permission from [22], copyright 2013, AIP
Publishing LLC). (c) Inertial separation. When the blood sample is pumped into the spiral channel, the centrifugal acceleration of fluid flow
will result in the formation of two symmetrical counter-rotating vortices across the channel.The smaller cell such as RBC andWBCwill move
along the vortices toward the inner wall and back to the outer wall, while larger CTCs will focus along the inner wall due to the additional
strong inertial lift forces (reprinted by permission from Macmillan Publishers Ltd.: Scientific Reports [23], copyright 2013). (d) Contraction
expansionmicrofluidic device. Dean drag forces are induced at the entrance of contraction region and thus result in blood sample which flow
through this region to have an influence by inertial lift force. RBC andWBCwill move toward 𝑠
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with permission from [24], copyright 2013, American Chemical Society).
technique is normally integrated with dielectrophoresis and
magnetophoresis method.
Apart of pinched flow fractionation, another promising
candidate of hydrodynamic based separation is deterministic
lateral displacement. This device is composed of an array of
posts (see Figure 5(b)), inwhich each row is displaced at a dis-
tance, Δ𝜆, from the previous row. Similar to microfiltration,
the dimension for both gap distance and obstacles size plays
pivotal role in the separation process.When a given particle is
smaller than the critical size, the particle will flow according
to themainstream line around the obstacle with nondeviating
trajectory perpendicular to streamline. However, if the parti-
cle is bigger than the critical size, it will collide with the obsta-
cle and results in streamline switch with a constant angle.
Such a motion is termed as lateral displacement. By tuning
the size of obstacle, the gap between them, and the shift in the
array, particles from different size can be separated laterally.
Using this technique, Davis et al. showed how the whole
blood could be continuously separated into its constituents
of erythrocytes, leukocytes, and plasma [105]. Despite its high
sensitivity, this study has highlighted that the flow rate used
in the device is relatively low compared to what would be
necessary for rare cells sorting. To investigate the optimal
flow rate for separation based on deterministic displacement,
Loutherback et al. have demonstrated the isolation of CTCs
from blood sample, within a long flow chamber filled with
mirrored array of 58𝜇m triangular posts with 42 𝜇m gaps.
Their result presented a very good CTCs capture efficiency
(>85%) at volumetric flow rate of 10mL/min, with no effect
on cell viability [22].
Inertial separation is another method which stands alone
tomanipulate particles in a continuous phase flow field. Con-
trary to both pinching flow fractionation and deterministic
lateral displacement, this method dominates the fluid inertial
lift force to accelerate the flowing particle to their preferential
equilibrium points. Such a phenomenon can be observed in
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the spiral microchannel. The presence of curvature structure
will generate rotational flow within the channel and thus
result in the formation of two symmetrical counter-rotating
vortices (top and bottom) across the channel cross section,
termed as Dean vortices [106]. This motion entrains particle
to move back and forth along the channel width. Coupled
with inertial lift force, the larger particles (such as tumor cells)
will occupy a single equilibrium position near the inner wall
while the smaller particle (red blood cells and white blood
cells) will migrate to the outer half of the channel, resulting in
the formation of distinct particle streams which are collected
in two separate outputs. Recently, a spiral device with 500𝜇m
wide and 160 𝜇m high using Dean flow induced motion
was developed by Hou et al. for CTCs isolation purpose.
When the device performance was tested with 3mL blood
suspension spiked with cancer cells (∼20% hematocrit), it
achieved high cancer cell recovery of >85% and high cell
viability (>98%). Besides, followed by preliminary clinical
testing, this device too had successfully detected CTCs in all
blood samples collected from 20 patients withmetastatic lung
cancer, ranging from 5 to 88 CTCs per mL [107]. As opposed
to Hou et al., Warkiani et al. investigated the performance
separation within a spiral channel with trapezoidal cross
section [35]. Their device had shown to achieve recovery
rate of 80% for 7.5mL of blood within 8 minutes. Similar
to Hou et al., they also verified their method successfully
being applicable to patient samples. However, such a device
requires proper geometrical design. For instance, a deeper
inner wall compared to the outer will cause strong vortices
forces to be formed at the inner side of the channel, resulting
in all particles to be trapped despite their different in size
and flow rate [108]. Apart of spiral structure, Lee et al. had
demonstrated their contraction-expansion array microchan-
nel device (Figure 5(d)) to be able to sort different cancer cell
lines out of the whole blood suspensions with a very high
capture efficiency up to 99.5% [24, 109].
3.3. Summary of Device Performance. For benchtop CTCs’
detection device, it is necessary to analyze and optimize the
devices’ performance before they are employed as clinical
diagnostic tools. The key performance metrics which are
widely highlighted in the literature included capture effi-
ciency (or recovery rate), throughput, viability, and purity.
Capture efficiency refers to the fraction of captured target
cells relative to the total captured cells. It is usually expressed
as a percentage (%).Thismeasurement is important in access-
ing the total of CTCs which has been lost in the isolation
process. A high capture efficiency represents less cell losses
and thus provides clinician accurate information about the
amount of CTCs discovered from patients’ blood sample.
Throughput indicates the speed at which the system can
process a sample. In most experiments, high throughput
device is favored by most researches as it allows a given
sample to be analyzed within the short timeThis parameter is
typically reported as either the volumetric flow or number of
cells processed per second. Meanwhile, viability can be best
described as the proportion of cells that remain “alive” and
“viable.” This viability is commonly assayed by dye exclusion
techniques where cells are incubated with a dilute solution of
dye which only enters dead cells. Maintenance of cell viability
is an imperative feature of cell separation procedure. For
instance, the capture living cells can be used for downstream
phenotypic and genotypic analyses. Furthermore, the cell
behavior can be correlated with cell number, providing a
more accurate picture of cell. Purity is defined as the percen-
tage of cells in separated population that are detected as
having certain design characteristics. It is an important indi-
cator for the purpose of downstream analysis as a high purity
indicates the cell subsets are not contaminated by nontarget
cells. Subsequently, it will increase the sensitivity of assay
used in postseparation analysis as well as provide accurate
information of targeted cell. Purity assessment is typically
conductedwith a flow cytometer, inwhich target cells labelled
with fluorescent markers are analyzed and the proportion of
each cell type in sample is calculated.
4. Conclusion and Future Outlook
In this review paper, we have highlighted the development of
several methods that exploit the physical characteristic of the
cells to isolate and differentiate CTCs. Although these devices
demonstrate significant progresses for CTCs isolation, the
development of these technologies is still in diverging phase,
in which methods described above are still at the proof of
concept level.There are some challenges that remain for these
devices to be fully employed in point-of-care application,
including the usage of cultured cancer cell line, the used of
whole blood sample, and low throughput.
Cultured cancer cell line is themostwidely used in bench-
top morphological model for CTCs, rarely yet on clinical
samples. Its model is generated by isolating a tumor cell from
a surgery sample and growing them in a controlled artificial
environment. Unlike primary tumors which can only be
maintained for a relatively short period of time in a reformu-
lated culture system [110], cancer cell line is immortalized and
genetically modified to proliferate indefinitely. Consequently,
it gives rise to a clonal population and thus allows various
scientific experiments to be carried out on these genetically
identical cancer cells. In spite of their important contribution
to cancer biology, several drawbacks are reported in the
literature. Review written by both Okita and Yamanaka [111]
and Holmberg and Perlmann [112] has indicated that tumor
does not proliferate at the same rate as cultured cells. In fact,
cultured cells are grown rapidly with doubling time much
shorter than those of cancer cell in vivo. When cultured
cancer cells are incubated in a growth promoting solution
for a long period of time, they will induce occurrence of
genomic changes, such as copy number variations as well
as transcriptomic drift. This condition undoubtedly affects
heterogeneity of cancer cell line and was proven in study
conducted byAuman andMcLeod [113]. Henceforth, the sep-
aration efficiency will be lower when the device is tested on
the clinical sample, in contrast to the cancer cell line. To tackle
this problem, effort should be made to develop new cell lines
that exhibit the genomic and transcriptomic heterogeneity of
cancer cell. Readers are encouraged to refer to Holmberg and
Perlmann paper for more information [112].
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As previously mentioned, CTCs can be detected in the
bloodstream as early as before a primary tumor is detected
with conventional clinical screening methods. As a result,
complete blood analysis is of prime interest for most CTCs
detection devices. Although the use of whole blood sample
is preferable for device performance evaluation, fractioning
various target components from it has been a technical chal-
lenge due to its massive number and wide diversity of cell
type. Up to the moment, only two techniques (such as mem-
brane microfilter device [15, 28, 29] and inertial separation
device [24, 34]) are reported with high capture efficiency
when the devices are tested with the whole blood samples
(refer to Table 1). Majority of techniques have demonstrated
a dramatic reduction in capture efficiency when the whole
blood sample is employed. To circumvent this problem, the
blood samples are generally diluted with isotonic diluent
before proceeding to benchtop separation process. Dilution
reduces the concentration of cell per unit volume and thus
allows for rapid detection of certain particles from dense
colonies. In fact, the presence of CTCs is extremely rare, 0
to 1 cells per millimeters of whole blood. Therefore, the use
of dilution buffer will be able to decrease the number of
CTCs within a sample, which in turn prolong the analysis
time. Furthermore, study conducted by Takaori in 1979 has
indicated that excessive dilution will cause a progressive
decrease in blood sample pH. Since blood cells respond
quickly to changes in microenvironment, their biological
characteristic might change with regard to the reduction
of pH. For instance, recent mathematical model developed
by Wolf and DeLand has indicated that hematocrit varies
with the change of blood pH [114]. In order to allow whole
blood sample to be analyzed with bench-separation device,
integration of multiple function such as enrichment and
detection method onto single chips should be attempted.
The enrichment technique (e.g., magnetophoresis) can be
employed in first stage to increase the sensitivity of the assay
by separating RBC from a human whole blood sample. This
is followed by a detection step (e.g., dielectrophoresis or
acoustophoresis) to separating target rare cells out from other
nucleated cells and residual RBCs.
Multiples studies have suggested that the use of microflu-
idic devices are extremely attractive for blood analysis as these
platforms allow miniaturization and integration of complex
functions. As a result, the complete lab for blood analysis is
feasible to be brought to patient’s bedside. Besides, microflu-
idic revolves around the precise manipulation of fluid flow
within channels, in which the dimension of the channel
cross section is smaller than 1mm2. Therefore, only minute
amounts of blood are needed for analysis and repetitive
sampling at multiple time points can be conducted. However,
there is a drawback of using these devices, such that most
of them are still rather limited in throughput. As shown in
Table 1, the throughput is achievable by most microfluidic
devices, lying around processing of 2 to 3mL of blood
per hours. Noteworthy, these devices are normally operated
slowly to maintain separation efficiency. However, for diag-
nostic application, 7.5mL of whole blood sample from patie-
nts is typically employed for CTCs enumeration. Henceforth,
the flow rate required for optimum throughput is probably
insufficient as it will take hours to complete the analysis. In
this case, the separation time is increased, which leads to a
loss of cell viability. Consequently, there is a need for resear-
chers to develop a microfluidic architecture which allow for
high throughput as well as enhancing the separation effi-
ciency and viability of CTCs.
In fact, a few microfluidic techniques discussed in this
paper has been commercialized for clinical diagnostic device
to isolate live CTCs from epithelial and nonepithelial malig-
nancies. These devices include ApoStream and ScreenCell.
ApoStream system, as illustrated in Figure 6, has been
launched by ApoCell laboratories in 2010 [115]. This tech-
nology leverages the dissimilarities of electrical properties
of different cell types to isolate CTCs with the assistance of
hydrodynamic force to position the cell at a defined level in a
fluid velocity gradient. Interdigitated electrodes are fabricated
on the chamber floor where the mixed cell population flows
over the electrode structure. Since CTC population expresses
positive DEP, it is pulled along the floor, flowing near the
electrode plane and collected through a port located in the
chamber floor, while the other cells (exhibiting negativeDEP)
are levitated and carried away by the eluent. Validation study
of ApoStream system conducted by Gupta et al. using human
blood sample spiked with breast cancer cell line (MDA-MB-
231) has successfully demonstrated a cell viability of 97.6%
with recovery efficiency of 86.6% [25]. In recognition of its
potential in CTCs isolation, in December 2014, ApoStream is
reported to be employed in BEACON (a Phase 3 open-label
and multicenter study of Etirinotecan pegol versus treatment
of physician’s choice (TPC) in patients with metastatic breast
cancer) to isolate CTCs for endpoint biomarker analysis [116].
The ScreenCell device is developed to support down-
stream analysis of captured CTCs, such as immunohisto-
chemistry and nucleic acid isolation. This device consists of
a filtration reservoir with a microporous membrane filter in a
removable nozzle holder. The whole blood sample is needed
to be diluted with standardized filtration buffer before it is
placed on the filtration reservoir for 3 minutes sample pro-
cessing time. To improve the throughput, vacuum is applied
to the outflow side of the filtration membrane. Similar to the
aforementioned membrane microfilter operating principle,
CTCs will be retained on the surface of filtration membrane
while small nucleated blood cell can easily pass through the
filtrationmembrane.Themembrane with captured CTC cells
can be removed from the device in the end of filtration
process for further manipulation. In 2011, ScreenCell study
conducted by Desitter et al. on whole blood sample spiked
with lung cancer cells has demonstrated a high recovery rate
of 91% and 74% for 5 and 2 cancer cells, respectively, per
mL of blood [117]. This device is further tested by Desitter
group in enumeration of CTCs from 23 cutaneousmelanoma
patients (CTCs does not express EpCAM) for the purpose
of cytological analysis and analysis of genetic mutations. The
postsurgery median of CTC recovery is 1 CTC per 2mL, with
15 of 23 patients being tested to be CTC-positive.
In conclusion, CTCs play an important role in both the
research lab and the clinic. Due to their role in metastasis,
information acquired from CTCs has the potential to assist
in prognosis as well as helping to define individualized
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Figure 6: Illustration of ApoStream device. The elution buffer is introduced at the upstream end of the flow chamber with a computer-
controlled gear pump.The blood sample is injected with a high precision syringe pump at a low flow rate into the bottom of the flow chamber
to reduce the cell levitation and to ensure that cells stay within effective DEP field. Under DEP field, the DEP forces will attract cancer cells
toward the electrodes on the chamber floors and vice versa to others cells. Cancer cells will withdraw through the collection port which is
located close to the chamber floor. Meanwhile, other blood cells will be levitated and flow into the waste container via a second outlet port
(reprinted with the permission from [25], copyright 2012, AIP Publishing LLC).
therapeutic regimens.Whilemethods based onEpCAMenri-
chment have brought CTC to point of care application,Newer
technologies which can facilitate CTC isolation as well as
support downstream analysis techniques are in dire need.The
features of user friendly and flexibility should be adapted into
the CTC isolation device design consideration to make the
technology available to more labs and clinic.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
This study is financially supported by University of Malaya,
High Impact Research Grant (UM.C/HIR/MOHE/ENG/44)
fromMinistry of Higher Education, Malaysia.
References
[1] N. Gaudin and V. Terrasse, Latest World Cancer Statistics
Global Cancer Burden Rises to 14.1 Million New Cases in 2012:
Marked Increase in Breast Cancers Must Be Addressed, vol. 2014,
International Agency for Research on Cancer, Lyon, France,
2013.
[2] H. Esmaeilsabzali, T. V. Beischlag, M. E. Cox, A. M.
Parameswaran, and E. J. Park, “Detection and isolation of
circulating tumor cells: principles and methods,” Biotechnology
Advances, vol. 31, no. 7, pp. 1063–1084, 2013.
[3] B. L. Ziober, M. G. Mauk, E. M. Falls, Z. Chen, A. F. Ziober,
and H. H. Bau, “Lab-on-a-chip for oral cancer screening and
diagnosis,” Head and Neck, vol. 30, no. 1, pp. 111–121, 2008.
[4] Y. Hu¨semann, J. B. Geigl, F. Schubert et al., “Systemic spread
is an early step in breast cancer,” Cancer Cell, vol. 13, no. 1, pp.
58–68, 2008.
[5] M. Farooqui, M. A. Hassali, A. Knight et al., “A qualitative
exploration of Malaysian cancer patients’ perceptions of cancer
screening,” BMC Public Health, vol. 13, article 48, 2013.
[6] D. Antolovic, L. Galindo, A. Carstens et al., “Heterogeneous
detection of circulating tumor cells in patients with colorec-
tal cancer by immunomagnetic enrichment using different
EpCAM-specific antibodies,”BMCBiotechnology, vol. 10, article
35, 2010.
[7] R. F. Swaby and M. Cristofanilli, “Circulating tumor cells in
breast cancer: a tool whose time has come of age,” BMC
Medicine, vol. 9, article 43, 2011.
[8] J. E. Allen and W. S. El-Deiry, “Circulating tumor cells and
colorectal cancer,” Current Colorectal Cancer Reports, vol. 6, no.
4, pp. 212–220, 2010.
[9] T. M. Geislinger and T. Franke, “Hydrodynamic lift of vesicles
and red blood cells in flow—from Fa˚hræus & Lindqvist to
microfluidic cell sorting,” Advances in Colloid and Interface
Science, vol. 208, pp. 161–176, 2014.
[10] D. L. Adams, P. Zhu, O. V. Makarova et al., “The systematic
study of circulating tumor cell isolation using lithographic
microfilters,” RSC Advances, vol. 4, no. 9, pp. 4334–4342, 2014.
[11] S. Zheng, H. K. Lin, B. Lu et al., “3D microfilter device for
viable circulating tumor cell (CTC) enrichment from blood,”
Biomedical Microdevices, vol. 13, no. 1, pp. 203–213, 2011.
[12] A. Yusa, M. Toneri, T. Masuda et al., “Development of a new
rapid isolation device for circulating tumor cells (CTCs) using
BioMed Research International 19
3Dpalladiumfilter and its application for genetic analysis,”PLoS
ONE, vol. 9, no. 2, Article ID e88821, 2014.
[13] M. D. Zhou, S. Hao, A. J. Williams et al., “Separable bilayer
microfiltration device for viable label-free enrichment of circu-
lating tumour cells,” Scientific Reports, vol. 4, article 7392, 2014.
[14] H. Hisamoto, T. Horiuchi, M. Tokeshi, A. Hibara, and T.
Kitamori, “On-chip integration of neutral ionophore-based ion
pair extraction reaction,”Analytical Chemistry, vol. 73, no. 6, pp.
1382–1386, 2001.
[15] J. Chung, H. Shao, T. Reiner, D. Issadore, R. Weissleder, and H.
Lee, “Microfluidic cell sorter (𝜇FCS) for on-chip capture and
analysis of single cells,” Advanced Healthcare Materials, vol. 1,
no. 4, pp. 432–436, 2012.
[16] J. S. Shim and C. H. Ahn, “An on-chip whole blood/plasma sep-
arator using hetero-packed beads at the inlet of amicrochannel,”
Lab on a Chip—Miniaturisation for Chemistry and Biology, vol.
12, no. 5, pp. 863–866, 2012.
[17] F. Petersson, L. A˚berg, A.-M. Swa¨rd-Nilsson, and T. Laurell,
“Free flow acoustophoresis:microfluidic-basedmode of particle
and cell separation,” Analytical Chemistry, vol. 79, no. 14, pp.
5117–5123, 2007.
[18] N. Lewpiriyawong, K. Kandaswamy, C. Yang, V. Ivanov, and R.
Stocker, “Microfluidic characterization and continuous separa-
tion of cells and particles using conducting poly(dimethyl silox-
ane) electrode induced alternating current-dielectrophoresis,”
Analytical Chemistry, vol. 83, no. 24, pp. 9579–9585, 2011.
[19] C.-T. Huang, T. G. Amstislavskaya, G.-H. Chen, H.-H. Chang,
Y.-H. Chen, and C.-P. Jen, “Selectively concentrating cervical
carcinoma cells from red blood cells utilizing dielectrophoresis
with circular ITO electrodes in stepping electric fields,” Journal
of Medical and Biological Engineering, vol. 33, no. 1, pp. 51–59,
2013.
[20] J. Takagi, M. Yamada, M. Yasuda, and M. Seki, “Continuous
particle separation in a microchannel having asymmetrically
arranged multiple branches,” Lab on a Chip—Miniaturisation
for Chemistry and Biology, vol. 5, no. 7, pp. 778–784, 2005.
[21] J. F. Ashley, C. N. Bowman, and R. H. Davis, “Hydrody-
namic separation of particles using pinched-flow fractionation,”
AIChE Journal, vol. 59, no. 9, pp. 3444–3457, 2013.
[22] K. Loutherback, J. D’Silva, L. Liu, A. Wu, R. H. Austin, and J. C.
Sturm, “Deterministic separation of cancer cells from blood at
10mL/min,”AIP Advances, vol. 2, no. 4, Article ID 042107, 2012.
[23] H. W. Hou, M. E. Warkiani, B. L. Khoo et al., “Isolation and
retrieval of circulating tumor cells using centrifugal forces,”
Scientific Reports, vol. 3, article 1259, 2013.
[24] M. G. Lee, C. Y. Bae, S. Choi, H.-J. Cho, and J.-K. Park, “Hight-
throughput inertial separation of cancer cells from human
whole blood in a contraction-expansion arraymicrochannel,” in
Proceedings of the 15th International Conference onMiniaturized
Systems for Chemistry and Life Sciences (MicroTAS ’11), pp.
2065–2067, Seattle, Wash, USA, October 2011.
[25] V. Gupta, I. Jafferji, M. Garza et al., “ApoStream, a new
dielectrophoretic device for antibody independent isolation and
recovery of viable cancer cells fromblood,”Biomicrofluidics, vol.
6, no. 2, Article ID 024133, 2012.
[26] O. Lara, X. Tong, M. Zborowski, and J. J. Chalmers, “Enrich-
ment of rare cancer cells through depletion of normal cells using
density and flow-through, immunomagnetic cell separation,”
Experimental Hematology, vol. 32, no. 10, pp. 891–904, 2004.
[27] R. Ko¨nigsberg, E. Obermayr, G. Bises et al., “Detection
of EpCAM positive and negative circulating tumor cells in
metastatic breast cancer patients,” Acta Oncologica, vol. 50, no.
5, pp. 700–710, 2011.
[28] B. Lu, T. Xu, S. Zheng, A. Goldkorn, and Y.-C. Tai, “Parylene
membrane slot filter for the capture, analysis and culture of
viable circulating tumor cells,” in Proceedings of the 23rd IEEE
International Conference on Micro Electro Mechanical Systems
(MEMS ’10), pp. 935–938, Wanchai, Hong Kong, January 2010.
[29] H. K. Lin, S. Zheng, A. J. Williams et al., “Portable filter-based
microdevice for detection and characterization of circulating
tumor cells,” Clinical Cancer Research, vol. 16, no. 20, pp. 5011–
5018, 2010.
[30] C. Arya, J. G. Kralj, K. Jiang et al., “Capturing rare cells from
blood using a packed bed of custom-synthesized chitosan mic-
roparticles,” Journal of Materials Chemistry B, vol. 1, no. 34, pp.
4313–4319, 2013.
[31] H.-S.Moon,K.Kwon, S.-I. Kimet al., “Continuous separation of
breast cancer cells from blood samples using multi-orifice flow
fractionation (MOFF) and dielectrophoresis (DEP),” Lab on a
Chip, vol. 11, no. 6, pp. 1118–1125, 2011.
[32] P. Augustsson, C. Magnusson, M. Nordin, H. Lilja, and T.
Laurell, “Microfluidic, label-free enrichment of prostate cancer
cells in blood based on acoustophoresis,” Analytical Chemistry,
vol. 84, no. 18, pp. 7954–7962, 2012.
[33] M. A. Burguillos, C. Magnusson, M. Nordin et al., “Microchan-
nel acoustophoresis does not impact survival or function of
microglia, leukocytes or tumor cells,” PLoS ONE, vol. 8, no. 5,
Article ID e64233, 2013.
[34] T. M. Geislinger and T. Franke, “Sorting of circulating tumor
cells (MV3-melanoma) and red blood cells using non-inertial
lift,” Biomicrofluidics, vol. 7, no. 4, Article ID 044120, 2013.
[35] M. E. Warkiani, G. Guan, K. B. Luan et al., “Slanted spiral
microfluidics for the ultra-fast, label-free isolation of circulating
tumor cells,” Lab on a Chip, vol. 14, no. 1, pp. 128–137, 2014.
[36] K. A. Rejniak, “Investigating dynamical deformations of tumor
cells in circulation: predictions from a theoretical model,”
Frontiers in Oncology, vol. 2, article 111, 2012.
[37] I. Dobrzyn´ska, E. Skrzydlewska, and Z. A. Figaszewski,
“Changes in electric properties of human breast cancer cells,”
Journal of Membrane Biology, vol. 246, no. 2, pp. 161–166, 2013.
[38] V. A. Loiko, G. L. Ruban, A. G. Olga, V. V. Berdnik, and N. V.
Goncharova,Mononuclear Cells Morphology for Cells Discrimi-
nation by Angular Structure of Scattered Light, Electromagnetic
and Light Scattering, Bodrum, Turkey, 2007.
[39] K. A. Gutowski, J. L. Hudson, andD. Aminoff, “Flow cytometric
analysis of human erythrocytes: I. Probed with lectins and
immunoglobulins,” Experimental Gerontology, vol. 26, no. 4, pp.
315–326, 1991.
[40] E. C. Lynch, “Peripheral blood smear,” in Clinical Methods: The
History, Physical, and Laboratory Examinations, H. K. Walker,
W. D. Hall, and J. W. Hurst, Eds., Butterworths, Boston, Mass,
USA, 1990.
[41] J. Seifter, D. Sloane, and A. Ratner, “Blood,” in Concepts in
Medical Physiology, B. Sun, Ed., p. 128, Lippincott Williams &
Wilkins, Philadelphia, Pa, USA, 2005.
[42] D. H. Cormack, Essential Histology, Lippincott Williams &
Wilkins, Philadelphia, Pa, USA, 2001.
[43] P. Pal, Textbok of Practical Physiology, Orient Blackswan, 2006.
[44] L. E. Eichelberger, M. O. Koch, J. N. Eble, T. M. Ulbright, B. E.
Juliar, and L. Cheng, “Maximum tumor diameter is an inde-
pendent predictor of prostate-specific antigen recurrence in
prostate cancer,” Modern Pathology, vol. 18, no. 7, pp. 886–890,
2005.
20 BioMed Research International
[45] R.Hass andC. Bertram, “Characterization of humanbreast can-
cer epithelial cells (HBCEC) derived from long term cultured
biopsies,” Journal of Experimental & Clinical Cancer Research,
vol. 28, no. 1, article 127, 2009.
[46] M. P. Wong, “Circulating tumor cells as lung cancer biomark-
ers,” Journal of Thoracic Disease, vol. 4, no. 6, pp. 631–634, 2012.
[47] V. J. Hofman, M. I. Ilie, C. Bonnetaud et al., “Cytopathologic
detection of circulating tumor cells using the isolation by size
of epithelial tumor cell method: promises and pitfalls,” The
American Journal of Clinical Pathology, vol. 135, no. 1, pp. 146–
156, 2011.
[48] C. L. Sommers, E. W. Thompson, J. A. Torri, R. Kemler, E. P.
Gelmann, and S.W. Byers, “Cell adhesionmolecule uvomorulin
expression in human breast cancer cell lines: relationship to
morphology and invasive capacities,” Cell Growth & Differen-
tiation, vol. 2, no. 8, pp. 365–372, 1991.
[49] P. A. Kenny, G. Y. Lee, C. A. Myers et al., “The morphologies
of breast cancer cell lines in three-dimensional assays correlate
with their profiles of gene expression,”Molecular Oncology, vol.
1, no. 1, pp. 84–96, 2007.
[50] S. Park, R. R. Ang, S. P. Duffy et al., “Morphological differences
between circulating tumor cells from prostate cancer patients
and cultured prostate cancer cells,” PLoS ONE, vol. 9, no. 1,
Article ID e85264, 2014.
[51] D. Marrinucci, K. Bethel, R. H. Bruce et al., “Case study of
the morphologic variation of circulating tumor cells,” Human
Pathology, vol. 38, no. 3, pp. 514–519, 2007.
[52] S. Tripathy and E. J. Berger, “Measuring viscoelasticity of soft
samples using atomic force microscopy,” Journal of Biomechan-
ical Engineering, vol. 131, no. 9, Article ID 094507, 2009.
[53] P. Roca-Cusachs, I. Almendros, R. Sunyer, N. Gavara, R. Farre´,
and D. Navajas, “Rheology of passive and adhesion-activated
neutrophils probed by atomic force microscopy,” Biophysical
Journal, vol. 91, no. 9, pp. 3508–3518, 2006.
[54] C.-L. Chen,D.Mahalingam, P.Osmulski et al., “Single-cell anal-
ysis of circulating tumor cells identifies cumulative expression
patterns of EMT-related genes in metastatic prostate cancer,”
Prostate, vol. 73, no. 8, pp. 813–826, 2013.
[55] A. L. Weisenhorn, M. Khorsandi, S. Kasas, V. Gotzos, and H.-J.
Butt, “Deformation and height anomaly of soft surfaces studied
with anAFM,”Nanotechnology, vol. 4, no. 2, article 106, pp. 106–
113, 1993.
[56] M. Mak and D. Erickson, “A serial micropipette microfluidic
device with applications to cancer cell repeated deformation
studies,” Integrative Biology (Camb), vol. 5, no. 11, pp. 1374–1384,
2013.
[57] A. Mohammadalipou, Y. E. Choi, F. Benencia, M. Burdick,
and D. F. J. Tees, “Investigation of mechanical properties of
breast cancer cells usingmicropipette aspiration technique,”The
Journal of the Federation of American Societies for Experimental
Biology, vol. 26, pp. 905–909, 2012.
[58] S. Byun, S. Son, D. Amodei et al., “Characterizing deformability
and surface friction of cancer cells,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 110, no.
19, pp. 7580–7585, 2013.
[59] H. W. Hou, Q. S. Li, G. Y. H. Lee, A. P. Kumar, C. N. Ong,
and C. T. Lim, “Deformability study of breast cancer cells using
microfluidics,” Biomedical Microdevices, vol. 11, no. 3, pp. 557–
564, 2009.
[60] C. Jin, S. M. McFaul, S. P. Duffy et al., “Technologies for
label-free separation of circulating tumor cells: from historical
foundations to recent developments,” Lab on a Chip, vol. 14, no.
1, pp. 32–44, 2014.
[61] T. G. Kuznetsova, M. N. Starodubtseva, N. I. Yegorenkov, S. A.
Chizhik, and R. I. Zhdanov, “Atomic force microscopy probing
of cell elasticity,”Micron, vol. 38, no. 8, pp. 824–833, 2007.
[62] S. E. Cross, Y.-S. Jin, J. Rao, and J. K. Gimzewski, “Nanomechan-
ical analysis of cells from cancer patients,” Nature Nanotechnol-
ogy, vol. 2, no. 12, pp. 780–783, 2007.
[63] A. Salmanzadeh, M. B. Sano, R. C. Gallo-Villanueva, P. C.
Roberts, E. M. Schmelz, and R. V. Davalos, “Investigating
dielectric properties of different stages of syngeneic murine
ovarian cancer cells,” Biomicrofluidics, vol. 7, Article ID 011809,
2013.
[64] R. O. Becker, “The bioelectric factors in amphibian-limb
regeneration,” The Journal of Bone & Joint Surgery—American
Volume, vol. 43, pp. 643–656, 1961.
[65] R. O. Becker, “The electrical control of growth processes,”
Medical Times, vol. 95, no. 6, pp. 657–669, 1967.
[66] R. O. Becker and D. G. Murray, “The electrical control
system regulating fracture healing in amphibians,” Clinical
Orthopaedics and Related Research, vol. 73, pp. 169–198, 1970.
[67] R. O. Becker, “The basic biological data transmission and
control system influenced by electrical forces,” Annals of the
New York Academy of Sciences, vol. 238, pp. 236–241, 1974.
[68] R. O. Becker and G. Selden, The Body Electric, W. Morrow &
Company, New York, NY, USA, 1985.
[69] J. C. Cure, “Electrical characteristics of cancer,” in Proceedings
of the 2nd International Congress of Electrochemical Treatment
of Cancer, Jupiter, Fla, USA, 1991.
[70] G. Qiao, W. Duan, C. Chatwin, A. Sinclair, and W. Wang,
“Electrical properties of breast cancer cells from impedance
measurement of cell suspensions,” Journal of Physics: Conference
Series, vol. 224, no. 1, Article ID 012081, 2010.
[71] F. F. Becker, X.-B. Wang, Y. Huang, R. Pethig, J. Vykoukal, and
P. R. C. Gascoyne, “Separation of human breast cancer cells
from blood by differential dielectric affinity,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 92, no. 3, pp. 860–864, 1995.
[72] GE Healthcare, Ficoll Paque PLUS: for In Vitro Isolation of
Lymphocytes, GE Healthcare, 2007.
[73] D. W. Fawcett, B. L. Vallee, and M. H. Soule, “A method for
concentration and segregation of malignant cells from bloody,
pleural, and peritoneal fluids,” Science, vol. 111, no. 2872, pp. 34–
36, 1950.
[74] S. H. Seal, “Silicone flotation: a simple quantitative method
for the isolation of free-floating cancer cells from the blood,”
Cancer, vol. 12, no. 3, pp. 590–595, 1959.
[75] N. Ahmadbeigi, M. Soleimani, F. Babaeijandaghi et al., “The
aggregate nature of humanmesenchymal stromal cells in native
bone marrow,” Cytotherapy, vol. 14, no. 8, pp. 917–924, 2012.
[76] R. T. van Beem, A. Hirsch, I. M. Lommerse et al., “Recovery
and functional activity of mononuclear bone marrow and
peripheral blood cells after different cell isolation protocols
used in clinical trials for cell therapy after acute myocardial
infarction,” EuroIntervention, vol. 4, no. 1, pp. 133–138, 2008.
[77] M. Aktas, T. F. Radke, B. E. Strauer, P. Wernet, and G. Kogler,
“Separation of adult bone marrow mononuclear cells using the
automated closed separation system Sepax,” Cytotherapy, vol.
10, no. 2, pp. 203–211, 2008.
[78] C. Po¨sel, K. Mo¨ller, W. Fro¨hlich, I. Schulz, J. Boltze, and D.-
C.Wagner, “Density gradient centrifugation compromises bone
BioMed Research International 21
marrow mononuclear cell yield,” PLoS ONE, vol. 7, no. 12,
Article ID e50293, 2012.
[79] W. M. Ellis, G. M. Georgiou, D. M. Roberton, and G. R.
Johnson, “Theuse of discontinuous percoll gradients to separate
populations of cells from human bone marrow and peripheral
blood,” Journal of Immunological Methods, vol. 66, no. 1, pp. 9–
16, 1984.
[80] Y. Chang, P.-H. Hsieh, and C. C.-K. Chao, “The efficiency of
Percoll and Ficoll density gradientmedia in the isolation ofmar-
row derived human mesenchymal stem cells with osteogenic
potential,” Chang Gung Medical Journal, vol. 32, no. 3, pp. 264–
275, 2009.
[81] R. Gertler, R. Rosenberg, K. Fuehrer, M. Dahm, H. Nekarda,
and J. Siewert, “Detection of circulating tumor cells in blood
using an optimized density gradient centrifugation,” inMolecu-
lar Staging of Cancer, H. Allgayer, M. Heiss, and F. Schildberg,
Eds., vol. 162 of Recent Results in Cancer Research, pp. 149–155,
Springer, Berlin, Germany, 2003.
[82] L. Zabaglo,M. G. Ormerod,M. Parton, A. Ring, I. E. Smith, and
M. Dowsett, “Cell filtration-laser scanning cytometry for the
characterisation of circulating breast cancer cells,” Cytometry
Part A, vol. 55, no. 2, pp. 102–108, 2003.
[83] J.-S. Shiau, C.-H. Tang, T.-Y. Lin, and D.-M. Wang, “A model
for resistance growthduring proteinmicrofiltration,” Separation
Science and Technology, vol. 38, no. 4, pp. 917–932, 2003.
[84] H. M. Ji, V. Samper, Y. Chen, C. K. Heng, T. M. Lim, and L.
Yobas, “Silicon-based microfilters for whole blood cell separa-
tion,” Biomedical Microdevices, vol. 10, no. 2, pp. 251–257, 2008.
[85] T. A. Crowley and V. Pizziconi, “Isolation of plasma fromwhole
blood using planar microfilters for lab-on-a-chip applications,”
Lab on a Chip, vol. 5, no. 9, pp. 922–929, 2005.
[86] C.-C. Wu, “Blood cell-free plasma separated from blood sam-
ples with a cascading Weir-type microfilter using dead-end
filtration,” Journal of Medical and Biological Engineering, vol. 32,
no. 3, pp. 163–168, 2012.
[87] W. Chen, N.-T. Huang, B. Oh et al., “Surface-micromachined
microfiltrationmembranes for efficient isolation and functional
immunophenotyping of subpopulations of immune cells,”
Advanced Healthcare Materials, vol. 2, no. 7, pp. 965–975, 2013.
[88] S. J. Tan, R. L. Lakshmi, P. Chen, W.-T. Lim, L. Yobas, and
C. T. Lim, “Versatile label free biochip for the detection
of circulating tumor cells from peripheral blood in cancer
patients,” Biosensors and Bioelectronics, vol. 26, no. 4, pp. 1701–
1705, 2010.
[89] W. Sheng, T. Chen, R. Kamath, X. Xiong,W. Tan, and Z. H. Fan,
“Aptamer-enabled efficient isolation of cancer cells from whole
bloodusing amicrofluidic device,”Analytical Chemistry, vol. 84,
no. 9, pp. 4199–4206, 2012.
[90] W. Ma, D. Liu, H. Shagoshtasbi et al., “Experimental and
theoretical study of hydrodynamic cell lysing of cancer cells
in a high-throughput Circular Multi-Channel Microfiltration
device,” in Proceedings of the 8th IEEE International Conference
on Nano/Micro Engineered and Molecular Systems (NEMS ’13),
pp. 412–415, IEEE, Suzhou, China, April 2013.
[91] F. Petersson, A. Nilsson, C. Holm, H. Jo¨nsson, and T. Laurell,
“Continuous separation of lipid particles from erythrocytes by
means of laminar flow and acoustic standing wave forces,” Lab
on a Chip, vol. 5, no. 1, pp. 20–22, 2005.
[92] L. M. Broche, N. Bhadal, M. P. Lewis, S. Porter, M. P. Hughes,
and F. H. Labeed, “Early detection of oral cancer—is dielec-
trophoresis the answer?” Oral Oncology, vol. 43, no. 2, pp. 199–
203, 2007.
[93] H. J.Mulhall, F.H. Labeed, B. Kazmi,D. E. Costea,M. P.Hughes,
and M. P. Lewis, “Cancer, pre-cancer and normal oral cells dis-
tinguished by dielectrophoresis,” Analytical and Bioanalytical
Chemistry, vol. 401, no. 8, pp. 2455–2463, 2011.
[94] F. Fabbri, S. Carloni, W. Zoli et al., “Detection and recovery of
circulating colon cancer cells using a dielectrophoresis-based
device: KRAS mutation status in pure CTCs,” Cancer Letters,
vol. 335, no. 1, pp. 225–231, 2013.
[95] C. Huang, H. Liu, N. H. Bander, and B. J. Kirby, “Enrich-
ment of prostate cancer cells from blood cells with a hybrid
dielectrophoresis and immunocapture microfluidic system,”
Biomedical Microdevices, vol. 15, no. 6, pp. 941–948, 2013.
[96] P. R. C. Gascoyne, X.-B. Wang, Y. Huang, and R. F. Becker,
“Dielectrophoretic separation of cancer cells from blood,” IEEE
Transactions on Industry Applications, vol. 33, no. 3, pp. 670–
678, 1997.
[97] A.Menachery andR. Pethig, “Controlling cell destruction using
dielectrophoretic forces,” IEE Proceedings Nanobiotechnology,
vol. 152, no. 4, pp. 145–149, 2005.
[98] D. M. Vykoukal, P. R. C. Gascoyne, and J. Vykoukal, “Dielectric
characterization of completemononuclear and polymorphonu-
clear blood cell subpopulations for label-free discrimination,”
Integrative Biology, vol. 1, no. 7, pp. 477–484, 2009.
[99] Y. Huang, J. Yang, X.-B. Wang, F. F. Becker, and P. R. C. Gas-
coyne, “The removal of human breast cancer cells from hema-
topoietic CD34+ stem cells by dielectrophoretic field-flow-
fractionation,” Journal of Hematotherapy & Stem Cell Research,
vol. 8, no. 5, pp. 481–490, 1999.
[100] A. Menachery, C. Kremer, P. E. Wong et al., “Counterflow
dielectrophoresis for trypanosome enrichment and detection in
blood,” Scientific Reports, vol. 2, article 775, 2012.
[101] X. Xing, M. Zhang, and L. Yobas, “Interdigitated 3-D silicon
ring microelectrodes for DEP-based particle manipulation,”
Journal of Microelectromechanical Systems, vol. 22, no. 2, Article
ID 6341027, pp. 363–371, 2013.
[102] L. Wang, J. Lu, S. A. Marchenko, E. S. Monuki, L. A. Flana-
gan, and A. P. Lee, “Dual frequency dielectrophoresis with
interdigitated sidewall electrodes for microfluidic flow-through
separation of beads and cells,” Electrophoresis, vol. 30, no. 5, pp.
782–791, 2009.
[103] T.-S. Leu and Z.-F. Liao, “Separating plasma and blood cells by
dielectrophoresis inmicrofluidic chips,” International Journal of
Modern Physics, vol. 19, pp. 185–189, 2012.
[104] B. I. Morshed, M. Shams, and T. Mussivand, “Electrical lysis:
dynamics revisited and advances in on-chip operation,” Critical
Reviews in Biomedical Engineering, vol. 41, no. 1, pp. 37–50, 2013.
[105] J. A. Davis, D. W. Inglis, K. J. Morton et al., “Deterministic
hydrodynamics: taking blood apart,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103, no.
40, pp. 14779–14784, 2006.
[106] A. A. S. Bhagat, H. W. Hou, L. D. Li, C. T. Lim, and J. Han,
“Pinched flow coupled shear-modulated inertial microfluidics
for high-throughput rare blood cell separation,” Lab on a Chip,
vol. 11, no. 11, pp. 1870–1878, 2011.
[107] L. Ying and Q. Wang, “Microfluidic chip-based technologies:
emerging platforms for cancer diagnosis,” BMC Biotechnology,
vol. 13, article 76, 2013.
[108] G. Guan, L. Wu, A. A. Bhagat et al., “Spiral microchannel
with rectangular and trapezoidal cross-sections for size based
particle separation,” Scientific Reports, vol. 3, article 1475, 2013.
22 BioMed Research International
[109] M. G. Lee, J. H. Shin, C. Y. Bae, S. Choi, and J.-K. Park, “Label-
free cancer cell separation from human whole blood using
inertial microfluidics at low shear stress,” Analytical Chemistry,
vol. 85, no. 13, pp. 6213–6218, 2013.
[110] D. L. Holliday and V. Speirs, “Choosing the right cell line for
breast cancer research,” Breast Cancer Research, vol. 13, no. 4,
article 215, 2011.
[111] K. Okita and S. Yamanaka, “Induced pluripotent stem cells:
opportunities and challenges,” Philosophical Transactions of the
Royal Society B: Biological Sciences, vol. 366, no. 1575, pp. 2198–
2207, 2011.
[112] J. Holmberg and T. Perlmann, “Maintaining differentiated
cellular identity,”Nature ReviewsGenetics, vol. 13, no. 6, pp. 429–
439, 2012.
[113] J. T. Auman and H. L. McLeod, “Colorectal cancer cell lines
lack the molecular heterogeneity of clinical colorectal tumors,”
Clinical Colorectal Cancer, vol. 9, no. 1, pp. 40–47, 2010.
[114] M. B.Wolf and E. C. DeLand, “Amathematical model of blood-
interstitial acid-base balance: application to dilution acidosis
and acid-base status,” Journal of Applied Physiology, vol. 110, no.
4, pp. 988–1002, 2011.
[115] A. Tan, “ApoCell receives $1 million Small Business Innovation
Research (SBIR) contract to develop a point-of-care clinical
device for Circulating Tumor Cell (CTC) Isolation,” BioNews
Texas, 2013.
[116] S. Hanner, “Biomarker-driven trial of novel topo-1 inhibitor
debuted,” Targeted Oncology. In press.
[117] I. Desitter, B. S. Guerrouahen, N. Benali-Furet et al., “A new
device for rapid isolation by size and characterization of rare
circulating tumor cells,” Anticancer Research, vol. 31, no. 2, pp.
427–441, 2011.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
